Article

Initiation of antiretroviral therapy leads to a rapid decline in cervical and vaginal HIV-1 shedding

Department of Medicine, University of Washington, Seattle, Washington, USA.
AIDS (Impact Factor: 6.56). 03/2007; 21(4):501-7. DOI: 10.1097/QAD.0b013e32801424bd
Source: PubMed

ABSTRACT Antiretroviral therapy (ART) may decrease HIV-1 infectivity in women by reducing genital HIV-1 shedding.
To evaluate the time course and magnitude of decay in cervical and vaginal HIV-1 shedding as women initiate ART.
This prospective, observational study of 20 antiretroviral-naive women initiating ART with stavudine, lamivudine, and nevirapine measured HIV-1 RNA in plasma, cervical secretions, and vaginal secretions. Qualitative polymerase chain reaction estimated HIV-1 DNA in cervical and vaginal samples. Perelson's two-phase viral decay model and non-linear random effects were used to compare RNA decay rates. Decreases in proviral DNA were evaluated using logistic regression and generalized estimating equations.
Significant decreases in the quantity of HIV-1 RNA were observed by day 2 in plasma (P < 0.001), day 2 in cervical secretions (P = 0.001), and day 4 in vaginal secretions (P < 0.001). Modeled initial and subsequent RNA decay rates in plasma, cervical secretions, and vaginal secretions were 0.6, 0.8, and 1.2 log10 virions/day, and 0.04, 0.05, and 0.06 log10 virions/day, respectively. The initial decay rate for vaginal HIV-1 RNA was more rapid than for plasma RNA (P = 0.02). Detection of HIV-1 DNA decreased significantly in vaginal secretions during the first week (P < 0.001). At day 28, 10 women had detectable HIV-1 RNA or proviral DNA in genital secretions.
Genital HIV-1 shedding decreased rapidly after ART initiation, consistent with a rapid decrease in infectivity. However, incomplete viral suppression in half of these women may indicate an ongoing risk of transmission.

0 Followers
 · 
83 Views
  • Source
    • "PrEP. WHO guidelines also define the clinical contraindications of PrEP with caution (Graham et al. 2007). Another major side-effect was hepatic flare (Lim et al. 2006, van Bommel et al. 2004). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Antiretroviral drugs are being tried as candidates for the pre-exposure prophylaxis (PrEP) against HIV for a considerable period, due to their potential for immediate inhibition of viral replication. Discrepancies in the findings called for a critical review of the relevant efforts and their outcomes. A systematic literature search identified 143 eligible articles of which only 5 reported complete findings while another 11 were still on-going. Observed moderate efficacy and good safety profile seemed to identify PrEP as a promising step for minimizing the spread of HIV to relatively unaffected population and controlling the epidemic among high risk population groups. But the duration of this efficacy was found to depend heavily on the availability, adherence and other related issues like cost, political commitment, ethical consideration etc. To prevent potential cultural and behavioral modifications, proper pre-administration counseling also seemed critical for the success of PrEP as a cost-effective intervention with adequate coverage.
    07/2014; DOI:10.3109/21691401.2014.934458
  • Source
    • "Drumright, Daar, & Little, 2006) (Inciardi, Surratt, Kurtz, & Weaver, 2005) (Patterson, Shaw, & Semple, 2003) (Brogly, Bruneau, Lamothe, Vincelette, & Franco, 2002) as well as a reduced viral load resulting from ART and thus reduced transmission (Quinn et al., 2000) (Vernazza et al., 2000) (Cu-Uvin et al., 2000; Fiore et al., 2003; Graham et al., 2007); (Hessol et al., 2007) (Kayitenkore K, "
    [Show abstract] [Hide abstract]
    ABSTRACT: With universal access to antiretroviral therapy (ART), people can access effective treatment but are only able to benefit from these advances if they are aware of their status and are effectively accessing testing services. Although it was anticipated in the mid-1990s that the availability of ART would lead to earlier testing, this trend has not been observed in practice, with stagnant or even increasing rates of late diagnosis in Europe. Ahead of a gathering of key European stakeholders in Brussels in November 2007, we reviewed definitions of late diagnosis and approaches to surveillance of late HIV diagnosis in Europe. We found that there is no common or consistent reporting of late diagnosis across Europe and that the multiplicity of definitions for late diagnosis is likely proving a hindrance to providing information on the magnitude of the problem, determining trends, and informing understanding of reasons for changes in trends. We also show that existing evidence points to high rates of late diagnosis across Europe - between 15 and 38% of all HIV cases - and concur that trends that are increasing or at best stagnant. We identify risk factors that are associated with individuals being more likely to present late and we explore the reasons for late presentation. We reflect on the need to review surveillance and testing policies, notably in relation for population groups that are heavily represented in late presenters and make recommendations for a coherent, cross-European approach to surveillance and monitoring in order to support improvements in service provision and, ultimately, public health.
    AIDS Care 12/2008; 21(3):284-93. DOI:10.1080/09540120802183537 · 1.60 Impact Factor
Show more